{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:37:04Z","timestamp":1789522624673,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health (NIH)","award":["RO1 HD094378"],"award-info":[{"award-number":["RO1 HD094378"]}]},{"name":"National Institutes of Health (NIH)","award":["RO1 ES028615"],"award-info":[{"award-number":["RO1 ES028615"]}]},{"name":"National Institutes of Health (NIH)","award":["U54 MD007602"],"award-info":[{"award-number":["U54 MD007602"]}]},{"name":"National Institutes of Health (NIH)","award":["RO1 HD094380"],"award-info":[{"award-number":["RO1 HD094380"]}]},{"name":"National Institutes of Health (NIH)","award":["R01HD087417"],"award-info":[{"award-number":["R01HD087417"]}]},{"name":"National Institutes of Health (NIH)","award":["HD106285"],"award-info":[{"award-number":["HD106285"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Uterine leiomyosarcoma (uLMS) is the most common type of uterine sarcoma associated with poor prognosis, high rates of recurrence, and metastasis. There is currently limited information about uLMS molecular mechanisms of origin and development. Bromodomain (BRD)-containing proteins are involved in many biological processes, most notably epigenetic regulation of transcription, and BRD protein dysfunction has been linked to many diseases including tumorigenesis. However, the role of BRD proteins in the pathogenesis of uLMS is unknown. Here, we show for the first time that BRD9 is aberrantly overexpressed in uLMS tissues compared to adjacent myometrium. BRD9 expression is also upregulated in uLMS cell lines compared to benign uterine fibroid and myometrium cell lines. Inhibition of BRD9 using the specific inhibitor (TP-472) suppressed uLMS cell proliferation via inducing apoptosis and cell cycle arrest. To further characterize the mechanistic basis for TP-472 inhibition of uLMS cell growth, we performed a comparative RNA-seq analysis of vehicle-treated and TP-472-treated uLMS cells (n = 4 each). Bioinformatics analysis revealed that TP-472 treatment distinctly altered the uLMS cell transcriptome. Gene set enrichment analysis identified critical pathways altered by BRD9 inhibition, including interferon-alpha response, KRAS signaling, MYC targets, TNF-a signaling via NFkB, and MTORC1 signaling. Parsimonious gene correlation network analysis identified nine enriched modules, including cell cycle and apoptosis modules. Moreover, the ENCODE Histone Modifications gene set and TargetScan microRNA analysis in Enrichr suggested that TP-472-induced BRD9 inhibition may alter the uLMS cell transcriptome by reprograming the oncogenic epigenome and inducing miRNA-mediated gene regulation. Therefore, BRD9 constitutes a specific vulnerability in malignant uLMS, and targeting non-BET BRD proteins in uLMS may provide a promising and novel strategy for treating patients with this aggressive uterine cancer.<\/jats:p>","DOI":"10.3390\/cells11142160","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T21:19:28Z","timestamp":1657487968000},"page":"2160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-8946","authenticated-orcid":false,"given":"Qiwei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2675-7936","authenticated-orcid":false,"given":"Maria Victoria","family":"Bariani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Falahati","sequence":"additional","affiliation":[{"name":"Department of Biology, Yazd University, Yazd 8915818411, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-4280","authenticated-orcid":false,"given":"Azad","family":"Khosh","sequence":"additional","affiliation":[{"name":"Department of Biology, Yazd University, Yazd 8915818411, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo R.","family":"Lastra","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Siblini","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-4447","authenticated-orcid":false,"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: A review","volume":"116","author":"Prat","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: Analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s43032-021-00731-y","article-title":"Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model","volume":"29","author":"Garcia","year":"2021","journal-title":"Reprod. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, Q., Ciebiera, M., Bariani, M.V., Ali, M., Elkafas, H., Boyer, T.G., and Al-Hendy, A. (2021). Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr. Rev.","DOI":"10.1210\/endrev\/bnab039"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrc.2016.61","article-title":"Epigenetics: Misdirecting methylation to drive oncogenesis","volume":"16","author":"Zuccala","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/onc.2016.485","article-title":"Interplay between epigenetics and metabolism in oncogenesis: Mechanisms and therapeutic approaches","volume":"36","author":"Wong","year":"2017","journal-title":"Oncogene"},{"key":"ref_9","first-page":"6299","article-title":"Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma","volume":"63","author":"Yang","year":"2003","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1158\/1078-0432.CCR-04-1331","article-title":"Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma","volume":"10","author":"Yang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yang, Q., Tian, Y., Ostler, K.R., Chlenski, A., Guerrero, L.J., Salwen, H.R., Godley, L.A., and Cohn, S.L. (2010). Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-286"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1749-6632.2003.tb05976.x","article-title":"Epigenetics in carcinogenesis and cancer prevention","volume":"983","author":"Jones","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1152\/japplphysiol.00066.2010","article-title":"Epigenetics and cancer","volume":"109","author":"Kanwal","year":"2010","journal-title":"J. Appl. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-61779-612-8_10","article-title":"Epigenetics of colon cancer","volume":"863","author":"Khare","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-61779-612-8_6","article-title":"Epigenetics of bladder cancer","volume":"863","author":"Kim","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1093\/hmg\/ddi113","article-title":"Cancer epigenetics","volume":"14","author":"Laird","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1933719115584449","article-title":"The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development","volume":"23","author":"Yang","year":"2016","journal-title":"Reprod. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jmb.2016.11.020","article-title":"Bromodomain Histone Readers and Cancer","volume":"429","author":"Jain","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1073\/pnas.0710331105","article-title":"Bromodomain 4 activation predicts breast cancer survival","volume":"105","author":"Crawford","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/cancers13010096","article-title":"The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer","volume":"13","author":"Leal","year":"2020","journal-title":"Cancers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-18-3776","article-title":"Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer","volume":"25","author":"Kregel","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77378","DOI":"10.18632\/oncotarget.12671","article-title":"MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells","volume":"7","author":"Kato","year":"2016","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13191","DOI":"10.2147\/OTT.S286867","article-title":"Targeting BRD9 for Cancer Treatment: A New Strategy","volume":"13","author":"Zhu","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/cancers11111634","article-title":"PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9","volume":"11","author":"Bell","year":"2019","journal-title":"Cancers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2019.01.007","article-title":"miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9","volume":"446","author":"Huang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41419-019-1570-9","article-title":"BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition","volume":"10","author":"Liu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41540-019-0090-7","article-title":"Parsimonious Gene Correlation Network Analysis (PGCNA): A tool to define modular gene co-expression for refined molecular stratification in cancer","volume":"5","author":"Care","year":"2019","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jacomy, M., Venturini, T., Heymann, S., and Bastian, M. (2014). ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098679"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr. Protoc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Supek, F., Bosnjak, M., Skunca, N., and Smuc, T. (2011). REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021800"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.fertnstert.2015.07.219","article-title":"Altered DNA repair genes in human uterine fibroids are epigenetically regulated via EZH2 histone methyltransferase","volume":"104","author":"Yang","year":"2015","journal-title":"Fertil. Steril."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/cancers13215516","article-title":"The BRD9\/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis","volume":"13","author":"Mason","year":"2021","journal-title":"Cancers"},{"key":"ref_35","first-page":"2319","article-title":"The Akt pathway in oncology therapy and beyond (Review)","volume":"53","author":"Nitulescu","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: A review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PPO.0b013e31803c74cf","article-title":"Utilization of chromatin remodeling agents for lung cancer therapy","volume":"13","author":"Schrump","year":"2007","journal-title":"Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"a018663","DOI":"10.1101\/cshperspect.a018663","article-title":"Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: Chemical modulation of chromatin structure","volume":"6","author":"Qi","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1874467212666190215112915","article-title":"Targeting Chromatin Remodeling for Cancer Therapy","volume":"12","author":"Kaur","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E1490","DOI":"10.1073\/pnas.1219992110","article-title":"Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer","volume":"110","author":"Magnani","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1158\/0008-5472.CAN-06-2597","article-title":"Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype","volume":"66","author":"Santillan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/epi.14.5","article-title":"Targeting the BET family for the treatment of leukemia","volume":"6","author":"Lucas","year":"2014","journal-title":"Epigenomics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.4049\/jimmunol.1202838","article-title":"BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses","volume":"190","author":"Belkina","year":"2013","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.18632\/oncotarget.3126","article-title":"JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer","volume":"6","author":"Qiu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/cancers12020304","article-title":"Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma","volume":"12","author":"Richter","year":"2020","journal-title":"Cancers"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2025182118","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"16330","DOI":"10.1038\/s41598-020-73500-7","article-title":"Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"643935","DOI":"10.3389\/fgene.2021.643935","article-title":"Gene Signature Associated With Bromodomain Genes Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jog.14037","article-title":"Case of leiomyosarcoma arising from subserosal leiomyoma","volume":"45","author":"Yamaguchi","year":"2019","journal-title":"J. Obs. Gynaecol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/nar\/gkz1120","article-title":"Different class IIa HDACs repressive complexes regulate specific epigenetic responses related to cell survival in leiomyosarcoma cells","volume":"48","author":"Dalla","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1039\/C6MD00373G","article-title":"Chemical probes and inhibitors of bromodomains outside the BET family","volume":"7","author":"Moustakim","year":"2016","journal-title":"Medchemcomm"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","article-title":"Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semcancer.2006.08.004","article-title":"Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function","volume":"16","author":"Hann","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2018.08.004","article-title":"Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups","volume":"34","author":"Archer","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbagrm.2014.06.002","article-title":"Myc and its interactors take shape","volume":"1849","author":"Tu","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.3389\/fmicb.2017.02686","article-title":"Hijacking of the AP-1 Signaling Pathway during Development of, A.T.L","volume":"8","author":"Gazon","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_59","first-page":"345","article-title":"Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters","volume":"27","author":"Langer","year":"2006","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/sj.onc.1204385","article-title":"Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity","volume":"20","author":"Chinenov","year":"2001","journal-title":"Oncogene"},{"key":"ref_61","first-page":"124","article-title":"Jun N-terminal kinase in rheumatoid arthritis","volume":"291","author":"Han","year":"1999","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/intimm\/11.1.47","article-title":"Serum response elements activate and cAMP responsive elements inhibit expression of transcription factor Egr-1 in synovial fibroblasts of rheumatoid arthritis patients","volume":"11","author":"Aicher","year":"1999","journal-title":"Int. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"642547","DOI":"10.3389\/fonc.2021.642547","article-title":"The Role of the Transcription Factor EGR1 in Cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eabf6045","DOI":"10.1126\/scitranslmed.abf6045","article-title":"Aberrant activation of m6A demethylase FTO renders HIF2alpha(low\/-) clear cell renal cell carcinoma sensitive to BRD9 inhibitors","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/cells10010053","article-title":"Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells","volume":"10","author":"Garcia","year":"2020","journal-title":"Cells"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.26502\/jcsct.5079089","article-title":"The Role of Hedgehog Pathway in Female Cancers","volume":"4","author":"Garcia","year":"2020","journal-title":"J. Cancer Sci. Clin. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1128\/MCB.23.11.3859-3871.2003","article-title":"Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a","volume":"23","author":"Bulavin","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/15384047.2017.1323601","article-title":"IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells","volume":"19","author":"Bhargava","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13048-017-0356-x","article-title":"The aberrant upstream pathway regulations of CDK1 protein were implicated in the proliferation and apoptosis of ovarian cancer cells","volume":"10","author":"Zhang","year":"2017","journal-title":"J. Ovarian Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.7150\/jca.51139","article-title":"CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer","volume":"12","author":"Ying","year":"2021","journal-title":"J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molcel.2019.05.015","article-title":"Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations","volume":"75","author":"Gothe","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1038\/onc.2014.332","article-title":"Topoisomerase IIalpha in chromosome instability and personalized cancer therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/81671","article-title":"Histone deacetylase interacts directly with DNA topoisomerase II","volume":"26","author":"Tsai","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e1517","DOI":"10.1210\/clinem\/dgz227","article-title":"Activation of beta-Catenin Signaling and its Crosstalk With Estrogen and Histone Deacetylases in Human Uterine Fibroids","volume":"105","author":"Ali","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1038\/s41598-021-95398-5","article-title":"Investigating crosstalk between H3K27 acetylation and H3K4 trimethylation in CRISPR\/dCas-based epigenome editing and gene activation","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.18632\/oncotarget.28032","article-title":"Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma","volume":"12","author":"Hasan","year":"2021","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"19379","DOI":"10.18632\/oncotarget.25056","article-title":"Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma","volume":"9","author":"Hu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/ijms22041580","article-title":"Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas","volume":"22","author":"Conconi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/cells8111452","article-title":"Let-7 miRNA\u2019s Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma","volume":"8","author":"Uno","year":"2019","journal-title":"Cells"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/cancers10090315","article-title":"Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and Carcinosarcoma Prognosis and Treatment?","volume":"10","author":"Soares","year":"2018","journal-title":"Cancers"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/14\/2160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:47:42Z","timestamp":1760140062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/14\/2160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,10]]},"references-count":80,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cells11142160"],"URL":"https:\/\/doi.org\/10.3390\/cells11142160","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,10]]}}}